deltatrials
Unknown PHASE3 INTERVENTIONAL NCT00078221

Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

Sponsor: OccuLogix

Conditions Macular Degeneration
Interventions Rheopheresis blood filtration
Updated 6 times since 2017 Last updated: May 8, 2008 Started: Aug 31, 1999 Completion: Dec 31, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00078221, this PHASE3 trial focuses on Macular Degeneration and remains ongoing. Sponsored by OccuLogix, it has been updated 6 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • OccuLogix
Data source: OccuLogix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations